ArticleFrontiers in immunology2022
Molecular Profile Sensitization to House Dust Mites as an Important Aspect for Predicting the Efficiency of Allergen Immunotherapy.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Evaluation of the Biological Standardization of Native Der p 1, Der p 2 and Der p 23 Proteins Isolated from Natural Allergen Source.International journal of molecular sciences · 2026Article
- Article
- Molecular profiling of IgE sensitization to dermatophagoides allergen components: clinical correlates in a high-exposure region.Frontiers in allergy · 2026Article
- Prospective Evaluation of Specific IgE Profile and Quality-of-Life During Allergen-Specific Immunotherapy with House Dust Mite: A Pilot Study.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Increased thyroxine levels of patients with allergic rhinitis.Scientific reports · 2025Article
- Improved quality control of allergen products: Assessing the molecular allergen composition by mass spectrometry.Allergy · 2024Article
- Sensitization profiles to house dust mite Dermatophagoides pteronyssinus molecular allergens in the Lithuanian population: Understanding allergic sensitization patterns.Clinical and translational allergy · 2024Article
- Fungi-sensitized individuals have unique profiles where Alt a 1 dominates promoting response to grass, ragweed and cat allergens.Frontiers in allergy · 2024Article
- Adjuvant-independent airway sensitization and infection mouse models leading to allergic asthma.Frontiers in allergy · 2024Review
- Comparative analysis of cysteine proteases reveals gene family evolution of the group 1 allergens in astigmatic mites.Clinical and translational allergy · 2023Article
- Identification of an immunodominant IgE epitope of Der f 40, a novel allergen ofThe World Allergy Organization journal · 2023Article
- Molecular Mapping of Allergen Exposome among Different Atopic Phenotypes.International journal of molecular sciences · 2023Article
- Molecular sensitization pattern to house dust mites is formed from the first years of life and includes group 1, 2, Der p 23, Der p 5, Der p 7 and Der p 21 allergens.Clinical and molecular allergy : CMA · 2023Article
- Frequent IgE recognition ofFrontiers in immunology · 2023Article
- Evaluation of Der p 10 in a Cohort of European Children: Role of Molecular Diagnostics and Clinical Features.Journal of immunology research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
House dust mite (HDM) allergens are considered to be one of the most common causes of asthma and allergic rhinitis in the world. Cysteine proteases Der p 1 and Der f 1 (group 1) and also NPC 2 family proteins Der p 2 and Der f 2 (group 2) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.